Fosun Pharma sold a 4.55% stake in Gland Pharma for Rs 2,121 crore, according to thehindubusinessline.com. The transaction marks a significant divestment by the Chinese pharmaceutical firm in the Indian injectable drug manufacturer. The sale was executed recently, reflecting Fosun Pharma's strategic portfolio adjustments.
The stake sale involved Fosun Pharma offloading shares in Gland Pharma, which is known for its injectable drug portfolio. The deal was completed through the stock market, with the shares changing hands at prevailing market prices. Fosun Pharma's decision to sell this portion of its holding aligns with its broader capital management strategy, as reported by thehindubusinessline.com.
This divestment is notable given Gland Pharma's position in the Indian pharmaceutical sector, especially in injectables, which is a growing segment. The Rs 2,121 crore deal adds to the trend of foreign investors recalibrating their stakes in Indian pharma companies. Gland Pharma has attracted significant attention from global investors due to its robust manufacturing capabilities and export-oriented business model.
Following this transaction, Fosun Pharma's remaining stake in Gland Pharma has been reduced, impacting its shareholding structure. The sale proceeds of Rs 2,121 crore will potentially be used by Fosun Pharma for other strategic investments or debt reduction, as per the company's financial disclosures. The transaction was confirmed by thehindubusinessline.com.